APOBEC3A

Across TCGA pan-cancer cohorts, APOBEC3A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated APOBEC3A data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher APOBEC3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOBEC3A expression acts as an unfavorable survival marker.

GBM and LUAD are the cancer types where APOBEC3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.062	0.416	.001	6	view →
LUAD	DFS	Median	All	0.244	0.767	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

APOBEC3A–GBM (OS)

Open the GBM breakdown →